Phase I Study Evaluating Combination Therapy With the Receptor Tyrosine Kinase Inhibitor PLX3397 and Sirolimus in Patients With Unresectable Sarcoma and Phase II Study in Malignant Peripheral Nerve Sheath Tumors
Phase of Trial: Phase I/II
Latest Information Update: 26 Sep 2017
At a glance
- Drugs Pexidartinib (Primary) ; Sirolimus
- Indications Nerve sheath neoplasms; Sarcoma
- Focus Adverse reactions; First in man; Therapeutic Use
- 19 Sep 2017 Planned End Date changed from 1 Oct 2017 to 1 Oct 2018.
- 19 Sep 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Oct 2018.
- 07 Jun 2016 Trial design presented at the 52nd Annual Meeting of the American Society of Clinical Oncology